Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.

[1]  M. Yamagishi,et al.  Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia , 2017, European heart journal.

[2]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[3]  S. Humphries,et al.  Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. , 2016, The lancet. Diabetes & endocrinology.

[4]  N. Seidah,et al.  Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor* , 2015, The Journal of Biological Chemistry.

[5]  K. Hayashi,et al.  Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. , 2015, The American journal of cardiology.

[6]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[7]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[8]  S. Yamashita,et al.  Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. , 2012, Journal of atherosclerosis and thrombosis.

[9]  K. Hayashi,et al.  Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. , 2012, The American journal of cardiology.

[10]  J. Kastelein,et al.  Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. , 2008, Journal of the American College of Cardiology.

[11]  C. Gieger,et al.  Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study , 2008, PloS one.

[12]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[13]  H. Gylling,et al.  Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. , 2005, The American journal of cardiology.

[14]  H. Mabuchi,et al.  Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[15]  Jonathan D. Cohen,et al.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.

[16]  H. Mabuchi,et al.  Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. , 2002, Atherosclerosis.

[17]  M. V. van’t Hof,et al.  The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. , 2000, Atherosclerosis.

[18]  P. Demacker,et al.  The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability. , 1999, Atherosclerosis.

[19]  D. Rader,et al.  Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. , 1993, The Journal of clinical investigation.

[20]  A. Hirayama,et al.  A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. , 2016, The American journal of cardiology.